Part 5/7:
While Icahn remains quiet about his exact plans for Allergan, Harjes suggested that the ongoing negotiations regarding a major sale of the company’s generics unit to Teva Pharmaceuticals for $40.5 billion could be a pivotal moment. With cash influx anticipated from potential sales, Icahn may take a more active role in advocating for how these funds should be allocated—whether it be debt reduction, special dividends, or other investor rewards.